Zobrazeno 1 - 10
of 91
pro vyhledávání: '"Aideen E Ryan"'
Autor:
Oliver Treacy, Hannah Egan, Aideen E Ryan, Li Peng, Michael O’Dwyer, Lizhi Cao, Jenny Che, Wayne Gatlin, Aoise O’Neill, Pushpa Jayaraman
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/d61b1d4bdd934ff1afb22cec1d28a816
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/8519f0e2937d475195b1b16847762c1a
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/0bf51a5556f741199091b08f7d725473
Autor:
Laurence Egan, Philip Dunne, Niamh Leonard, Oliver Treacy, Hannah Egan, Thomas Ritter, Daniela Loessner, Margaret Sheehan, Sean Hynes, Aisling Hogan, Aideen E Ryan, Keara Redmond, Aoife Canney, Shania Corry, Eileen Reidy
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/13dc525d42d44aa4901043dbf714840f
Autor:
Daniel Olson, Jiajia Zhang, Todd Bartkowiak, Abdul Rafeh Naqash, Vaia Florou, Rosa Nguyen, Rania H Younis, Sarah Church, Maria E Rodriguez-Ruiz, Rachel Howard, Thomas U Marron, Ravi B Patel, Michal Sheffer, Abigail Overacre-Delgoffe, Aideen E Ryan, Sangeetha M Reddy, Sabina Kaczanowska, Dipti Thakkar, Kristin G Anderson, Esha Sachdev, Christopher Fuhrman, Jessica E Thaxton, David H Aggen, Jennifer L Guerriero
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 3 (2021)
Immune checkpoint inhibitors (ICIs) have improved overall survival for cancer patients, however, optimal duration of ICI therapy has yet to be defined. Given ICIs were first used to treat patients with metastatic melanoma, a condition that at the tim
Externí odkaz:
https://doaj.org/article/7d235762c1ba404981eaf9960cd816b9
Autor:
Serika D Naicker, Claire L Feerick, Kevin Lynch, Dawn Swan, Cian McEllistrim, Robert Henderson, Niamh A Leonard, Oliver Treacy, Alessandro Natoni, Athina Rigalou, Joana Cabral, Christopher Chiu, Kate Sasser, Thomas Ritter, Michael O’Dwyer, Aideen E Ryan
Publikováno v:
OncoImmunology, Vol 10, Iss 1 (2021)
Multiple Myeloma (MM) is a malignant disorder of plasma cells which, despite significant advances in treatment, remains incurable. Daratumumab, the first CD38 directed monoclonal antibody, has shown promising activity alone and in combination with ot
Externí odkaz:
https://doaj.org/article/c2aa7a8efc5244f4b92d73ee74984420
Autor:
Oliver Treacy, Aideen E Ryan, Teresa Heinzl, Lisa O'Flynn, Marese Cregg, Mieszko Wilk, Francesca Odoardi, Paul Lohan, Timothy O'Brien, Mikhail Nosov, Thomas Ritter
Publikováno v:
PLoS ONE, Vol 7, Iss 8, p e42662 (2012)
Adult mesenchymal stem cells (MSCs) are non-hematopoietic cells with multi-lineage potential which makes them attractive targets for regenerative medicine applications. However, to date, therapeutic success of MSC-therapy is limited and the genetic m
Externí odkaz:
https://doaj.org/article/55d431c8d85e47059b111fe8ebca5251
Publikováno v:
HemaSphere, Vol 4, Iss 2, p e350 (2020)
Abstract. The alkylating agent cyclophosphamide has been used in the treatment of multiple myeloma for over 60 years. At low doses, cyclophosphamide also has significant immunomodulatory activity, which can be used to modify the immunosuppressive tum
Externí odkaz:
https://doaj.org/article/57d9331d24ec4e129c0aba735d72de5f
Autor:
Hannah Egan, Oliver Treacy, Kevin Lynch, Niamh A. Leonard, Grace O’Malley, Eileen Reidy, Aoise O’Neill, Shania M. Corry, Kim De Veirman, Karin Vanderkerken, Laurence J. Egan, Thomas Ritter, Aisling M. Hogan, Keara Redmond, Li Peng, Jenny Che, Wayne Gatlin, Pushpa Jayaraman, Margaret Sheehan, Aoife Canney, Sean O. Hynes, Emma M. Kerr, Philip D. Dunne, Michael E. O’Dwyer, Aideen E. Ryan
Immunosuppressive tumor microenvironments (TMEs) reduce the effectiveness of immune responses in cancer. Mesenchymal stromal cells (MSCs), precursors to cancer-associated fibroblasts (CAFs), promote tumor progression by enhancing immune cell suppress
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ed5a9ff18739c6840bf4580074fd3b70
https://biblio.vub.ac.be/vubir/targeting-stromal-cell-sialylation-reverses-t-cellmediated-immunosuppression-in-the-tumor-microenvironment(1322be90-3ac7-43dd-8494-4ed572cf07ad).html
https://biblio.vub.ac.be/vubir/targeting-stromal-cell-sialylation-reverses-t-cellmediated-immunosuppression-in-the-tumor-microenvironment(1322be90-3ac7-43dd-8494-4ed572cf07ad).html
Autor:
Aideen E. Ryan, Laurence J. Egan, Thomas Ritter, Philip D. Dunne, Paul Lohan, Niamh A. Leonard, Serika D. Naicker, Kevin Lynch, Oliver Treacy, Grace O'Malley
Characterisation of primary BALB/c MSCs isolated from bone marrow, PD-L1 induction on MSC TNF-TCM is dependent on CT26 NF-κB activity, Validation of scrambled and PD-L1 shRNA transduced Balb/c MSCs - GFP expression and PD-L1 inhibition, Tumour burde
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::86a61c546552ef02c383997114c02e32
https://doi.org/10.1158/2326-6066.22538954.v1
https://doi.org/10.1158/2326-6066.22538954.v1